目的探讨树突状细胞负载胶质瘤细胞肿瘤疫苗治疗脑胶质瘤母细胞的临床疗效。方法将64例脑胶质瘤患者随机均分为两组,两组均采用传统的手术及术后放化疗治疗,实验组在此基础上采用树突状细胞负载胶质瘤细胞肿瘤疫苗联合术后放化疗治疗,比较两组的疗效。结果放化疗后,实验组完全缓解者17例,部分缓解11例,稳定病变4例,有效28例,有效率为87.50%;对照组完全缓解者13例,部分缓解8例,稳定病变11例,有效21例,有效率为65.63%。两组有效率比较差异有统计学意义(χ2=4.2667,P=0.0389),实验组高于对照组;实验组1、3年生存率分别为100.0%、68.9%,对照组1、3年生存率分别为100.0%、52.7%,实验组疗效优于对照组(χ2=4.231,P=0.014);实验组接种疫苗后不良反应发生率34.38%,对照组31.25%,两组差异无统计学意义(χ2=0.071,P=0.790)。结论采用树突状细胞负载胶质瘤细胞肿瘤疫苗联合术后放化疗治疗脑胶质瘤患者疗效较好,有重要临床参考价值。 Objective To investigate the clinical efficacy of dendritic cells loaded glioma tumor vaccine on glioma blast cells. Methods Sixty-four patients with glioma were randomly divided into two groups. Both groups were treated by traditional surgery and postoperative radiotherapy and chemotherapy. On the basis of this, the experimental group was treated with dendritic cells loaded glioma tumor vaccine After radiotherapy and chemotherapy, the two groups were compared. Results After radiotherapy and chemotherapy, 17 cases were completely relieved in the experimental group, 11 cases were partially relieved, 4 cases were stable and 28 cases were effective, the effective rate was 87.50%. In the control group, 13 cases were completely relieved, 8 cases partially relieved and 11 cases stable , Effective in 21 cases, the effective rate was 65.63%. The effective rates of the two groups were statistically significant (χ2 = 4.2667, P = 0.0389), the experimental group was higher than the control group; the 1-year and 3-year survival rates of the experimental group were 100.0% and 68.9% (Χ2 = 4.231, P = 0.014). The incidence of adverse reactions in experimental group was 34.38% after vaccination and 31.25% in control group, there was no significant difference between the two groups (χ2 = 0.071, P = 0.790). Conclusion The dendritic cells loaded glioma tumor vaccine combined with postoperative radiotherapy and chemotherapy in patients with glioma has good curative effect and has important clinical reference value.